PE20191362A1 - Novedoso vector del subtipo f del virus adenoasociado (aav) y usos de este - Google Patents
Novedoso vector del subtipo f del virus adenoasociado (aav) y usos de esteInfo
- Publication number
- PE20191362A1 PE20191362A1 PE2019001786A PE2019001786A PE20191362A1 PE 20191362 A1 PE20191362 A1 PE 20191362A1 PE 2019001786 A PE2019001786 A PE 2019001786A PE 2019001786 A PE2019001786 A PE 2019001786A PE 20191362 A1 PE20191362 A1 PE 20191362A1
- Authority
- PE
- Peru
- Prior art keywords
- associated virus
- seq
- aavhu68
- adeno
- aav
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Un vector de virus adenoasociado recombinante (rAAV), que comprende una capside de AAVhu68 producida en un sistema de produccion que comprende una secuencia de nucleotidos de la SEQ ID NO: 1, o una secuencia al menos 75 % identica a esta, que codifica la SEQ ID N0:2. La capside de AAVhu68 comprende subpoblaciones de residuos de asparagina muy desamidados en los pares de asparagina-glicina en la secuencia de aminoacidos de la SEQ ID NO: 2. Tambien se proporcionan composiciones que contienen el rAAV y usos de estas. Ademas, se proporcionan rAAV que tienen una capside de AAV modificada, que comprende al menos una subpoblacion de proteinas vp1 o vp2 con una Val en la posicion de aminoacidos 157, con referencia a la numeracion de vp1 de AAVhu68
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762464748P | 2017-02-28 | 2017-02-28 | |
US201762591002P | 2017-11-27 | 2017-11-27 | |
US201862614002P | 2018-01-05 | 2018-01-05 | |
PCT/US2018/019992 WO2018160582A1 (en) | 2017-02-28 | 2018-02-27 | Adeno-associated virus (aav) clade f vector and uses therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20191362A1 true PE20191362A1 (es) | 2019-10-01 |
Family
ID=61628475
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2019001786A PE20191362A1 (es) | 2017-02-28 | 2018-02-27 | Novedoso vector del subtipo f del virus adenoasociado (aav) y usos de este |
Country Status (23)
Country | Link |
---|---|
US (2) | US11827906B2 (es) |
EP (2) | EP4272765A3 (es) |
JP (2) | JP7455579B2 (es) |
KR (1) | KR20190132639A (es) |
CN (1) | CN110741082A (es) |
BR (1) | BR112019017839A2 (es) |
CA (1) | CA3053399A1 (es) |
CL (1) | CL2019002474A1 (es) |
CO (1) | CO2019009525A2 (es) |
DK (1) | DK3589730T3 (es) |
FI (1) | FI3589730T3 (es) |
HR (1) | HRP20240257T1 (es) |
IL (1) | IL268644A (es) |
LT (1) | LT3589730T (es) |
MD (1) | MD3589730T2 (es) |
MX (1) | MX2019010275A (es) |
PE (1) | PE20191362A1 (es) |
PT (1) | PT3589730T (es) |
RS (1) | RS65241B1 (es) |
SG (4) | SG10201912976WA (es) |
SI (1) | SI3589730T1 (es) |
WO (1) | WO2018160582A1 (es) |
ZA (1) | ZA201905407B (es) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2406745C (en) | 2001-11-13 | 2006-01-10 | The Trustees Of The University Of Pennsylvania | A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby |
EP3211085B1 (en) | 2003-09-30 | 2021-03-31 | The Trustees of The University of Pennsylvania | Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor |
JP7064214B2 (ja) | 2015-09-28 | 2022-05-10 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 抗体回避性ウイルスベクターのための方法および組成物 |
IL310925A (en) * | 2016-01-15 | 2024-04-01 | American Gene Tech Int Inc | Methods and preparations for activating GAMMA-DELTA T cells |
JOP20190200A1 (ar) | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | تركيبات نافعة في معالجة ضمور العضل النخاعي |
JP7455579B2 (ja) | 2017-02-28 | 2024-03-26 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 新規アデノ随伴ウイルス(aav)クレードfベクター及びその用途 |
RU2019139555A (ru) | 2017-05-11 | 2021-06-11 | Зе Трастис Оф Зе Юниверсити Оф Пеннсильвания | Генная терапия нейрональных цероидных липофусцинозов |
AU2018375164A1 (en) | 2017-11-30 | 2020-06-04 | The Trustees Of The University Of Pennsylvania | Gene therapy for Mucopolysaccharidosis IIIA |
WO2019108856A1 (en) | 2017-11-30 | 2019-06-06 | The Trustees Of The University Of Pennsylvania | Gene therapy for mucopolysaccharidosis iiib |
MX2020008932A (es) * | 2018-02-27 | 2020-10-01 | Univ Pennsylvania | Novedosos vectores de virus adenoasociado (aav), vectores de aav que tienen una desamidacion reducida de la capside y usos de estos. |
CA3091806A1 (en) * | 2018-02-27 | 2019-09-06 | The Trustees Of The University Of Pennsylvania | Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor |
EP3774854A1 (en) | 2018-04-03 | 2021-02-17 | Stridebio, Inc. | Antibody-evading virus vectors |
CN113438954A (zh) * | 2018-10-01 | 2021-09-24 | 宾夕法尼亚州大学信托人 | 可用于治疗gm1神经节苷脂病的组合物 |
UY38407A (es) | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
EP3924364A1 (en) | 2019-02-15 | 2021-12-22 | Sangamo Therapeutics, Inc. | Compositions and methods for producing recombinant aav |
TW202045730A (zh) | 2019-02-22 | 2020-12-16 | 賓州大學委員會 | 用於治療grn相關的成年發病型神經系統退化症之重組腺相關病毒 |
MX2021010266A (es) | 2019-02-26 | 2021-09-23 | Univ Pennsylvania | Composiciones utiles en el tratamiento de la enfermedad de krabbe. |
EA202192501A1 (ru) | 2019-03-21 | 2021-12-16 | Страйдбайо, Инк. | Рекомбинантные аденоассоциированные вирусные векторы |
WO2020219766A1 (en) * | 2019-04-24 | 2020-10-29 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of rett syndrome |
CA3135539A1 (en) * | 2019-05-03 | 2020-11-12 | Juliette HORDEAUX | Compositions useful in treatment of metachromatic leukodystrophy |
WO2021076925A1 (en) | 2019-10-17 | 2021-04-22 | Stridebio, Inc. | Adeno-associated viral vectors for treatment of niemann-pick disease type c |
AU2020398904A1 (en) * | 2019-12-10 | 2022-06-30 | Homology Medicines, Inc. | Adeno-associated virus compositions and methods of use thereof |
WO2021155337A1 (en) | 2020-02-02 | 2021-08-05 | The Trustees Of The University Of Pennsylvania | Compositions useful for treating gm1 gangliosidosis |
CA3177407A1 (en) | 2020-05-12 | 2021-11-18 | James M. Wilson | Compositions for drg-specific reduction of transgene expression |
KR20230023637A (ko) | 2020-05-12 | 2023-02-17 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 크라베병의 치료에 유용한 조성물 |
EP4158037A1 (en) | 2020-05-26 | 2023-04-05 | Shape Therapeutics Inc. | High throughput engineering of functional aav capsids |
CN116438311A (zh) | 2020-07-13 | 2023-07-14 | 宾夕法尼亚州大学信托人 | 可用于治疗夏科-马里-图思病的组合物 |
GB2599212A (en) | 2020-07-30 | 2022-03-30 | Shape Therapeutics Inc | Stable cell lines for inducible production of rAAV virions |
EP4200429A1 (en) | 2020-08-24 | 2023-06-28 | The Trustees of The University of Pennsylvania | Viral vectors encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases |
CN116887867A (zh) | 2020-08-26 | 2023-10-13 | 宾夕法尼亚州大学信托人 | 用于治疗grn相关成人发作性神经退行性病变的重组腺相关病毒 |
EP4225906A1 (en) | 2020-10-09 | 2023-08-16 | The Trustees of The University of Pennsylvania | Compositions and methods for treatment of fabry disease |
AR123838A1 (es) | 2020-10-18 | 2023-01-18 | Univ Pennsylvania | Vector mejorado de virus adenoasociado (aav) y usos de este |
WO2022094078A1 (en) | 2020-10-28 | 2022-05-05 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of rett syndrome |
WO2022094255A2 (en) * | 2020-10-29 | 2022-05-05 | Regenxbio Inc. | Vectorized factor xii antibodies and administration thereof |
JP2023550581A (ja) * | 2020-10-29 | 2023-12-04 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | Aavカプシド及びそれを含有する組成物 |
JP2023548432A (ja) | 2020-11-11 | 2023-11-16 | ヨーロピアン モレキュラー バイオロジー ラボラトリー | 遺伝子療法のための改変ウイルス粒子 |
CA3200014A1 (en) | 2020-12-01 | 2022-06-09 | James M. Wilson | Novel compositions with tissue-specific targeting motifs and compositions containing same |
CA3200192A1 (en) | 2020-12-01 | 2022-06-09 | Justin PERCIVAL | Compositions and uses thereof for treatment of angelman syndrome |
JP2024505257A (ja) | 2021-02-01 | 2024-02-05 | レジェンクスバイオ インコーポレーテッド | 神経セロイドリポフスチン症の遺伝子治療 |
EP4323520A1 (en) | 2021-04-12 | 2024-02-21 | The Trustees of The University of Pennsylvania | Compositions useful for treating spinal and bulbar muscular atrophy (sbma) |
BR112023021971A2 (pt) | 2021-04-23 | 2024-02-20 | Univ Pennsylvania | Composições com motivos de direcionamento específicos do cérebro e composições contendo os mesmos |
BR112023023599A2 (pt) | 2021-05-12 | 2024-03-12 | Fond Telethon | Sistema de vetor |
IL308787A (en) * | 2021-06-08 | 2024-01-01 | Univ Pennsylvania | Recombinant adeno-associated viruses for Leish-Nihan disorders and their uses |
WO2023056399A1 (en) | 2021-10-02 | 2023-04-06 | The Trustees Of The University Of Pennsylvania | Novel aav capsids and compositions containing same |
WO2023087019A2 (en) | 2021-11-15 | 2023-05-19 | The Trustees Of The University Of Pennsylvania | Compositions for drg-specific reduction of transgene expression |
WO2023102079A1 (en) | 2021-12-01 | 2023-06-08 | Shape Therapeutics Inc. | Functional aav capsids for systemic administration |
WO2023102078A2 (en) | 2021-12-01 | 2023-06-08 | Shape Therapeutics Inc. | Functional aav capsids for intravitreal administration |
WO2023102517A1 (en) | 2021-12-02 | 2023-06-08 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of fabry disease |
WO2023133584A1 (en) | 2022-01-10 | 2023-07-13 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of metachromatic leukodystrophy |
WO2023133574A1 (en) | 2022-01-10 | 2023-07-13 | The Trustees Of The University Of Pennsylvania | Compositions and methods useful for treatment of c9orf72-mediated disorders |
WO2023147304A1 (en) | 2022-01-25 | 2023-08-03 | The Trustees Of The University Of Pennsylvania | Aav capsids for improved heart transduction and detargeting of liver |
WO2023196892A1 (en) | 2022-04-06 | 2023-10-12 | The Trustees Of The University Of Pennsylvania | Passive immunization with anti- aav neutralizing antibodies to prevent off-target transduction of intrathecally delivered aav vectors |
WO2023196893A1 (en) | 2022-04-06 | 2023-10-12 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating her2 positive metastatic breast cancer and other cancers |
WO2023214346A1 (en) | 2022-05-06 | 2023-11-09 | Novartis Ag | Novel recombinant aav vp2 fusion polypeptides |
WO2023220695A2 (en) * | 2022-05-13 | 2023-11-16 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
Family Cites Families (141)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
US6268213B1 (en) | 1992-06-03 | 2001-07-31 | Richard Jude Samulski | Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy |
US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
US5869305A (en) | 1992-12-04 | 1999-02-09 | The University Of Pittsburgh | Recombinant viral vector system |
JPH08506144A (ja) | 1993-02-05 | 1996-07-02 | ラポート グループ オーストラリア リミティド | スラグ脱泡複合材料 |
US5834266A (en) | 1993-02-12 | 1998-11-10 | President & Fellows Of Harvard College | Regulated apoptosis |
US20020173474A1 (en) | 1993-02-12 | 2002-11-21 | President And Fellows Of Harvard College | Methods & materials involving dimerization-mediated regulation of biological events |
US6140120A (en) | 1993-02-12 | 2000-10-31 | Board Of Trustees Of Leland Stanford Jr. University | Regulated transcription of targeted genes and other biological events |
JP3824633B2 (ja) | 1993-02-12 | 2006-09-20 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・リランド・スタンフォード・ジュニアー・ユニバーシティ | 標的遺伝子の調節的転写および他の生物学的結果 |
US5869337A (en) | 1993-02-12 | 1999-02-09 | President And Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
US6972193B1 (en) | 1993-02-12 | 2005-12-06 | Board Of Trustees Of Leland Stanford Junior University | Regulated transcription of targeted genes and other biological events |
US5830462A (en) | 1993-02-12 | 1998-11-03 | President & Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
US6150137A (en) | 1994-05-27 | 2000-11-21 | Ariad Pharmaceuticals, Inc. | Immunosuppressant target proteins |
US6476200B1 (en) | 1994-06-27 | 2002-11-05 | The Johns Hopkins University | Mammalian proteins that bind to FKBP12 in a rapamycin-dependent fashion |
US6204059B1 (en) | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
US6133456A (en) | 1994-08-18 | 2000-10-17 | Ariad Gene Therapeutics, Inc. | Synthetic multimerizing agents |
US6150527A (en) | 1994-08-18 | 2000-11-21 | Ariad Pharmaceuticals, Inc. | Synthetic multimerizing agents |
AU3367995A (en) | 1994-08-18 | 1996-03-14 | Ariad Pharmaceuticals, Inc. | New multimerizing agents |
US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
US6326166B1 (en) | 1995-12-29 | 2001-12-04 | Massachusetts Institute Of Technology | Chimeric DNA-binding proteins |
AU719001B2 (en) | 1994-12-29 | 2000-05-04 | Massachusetts Institute Of Technology | Chimeric DNA-binding proteins |
US6166197A (en) | 1995-03-06 | 2000-12-26 | Isis Pharmaceuticals, Inc. | Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions |
CA2219080A1 (en) | 1995-06-07 | 1996-12-27 | Ariad Gene Therapeutics, Inc. | Rapamycin-based regulation of biological events |
US5811524A (en) | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
US5741683A (en) | 1995-06-07 | 1998-04-21 | The Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
US6506379B1 (en) | 1995-06-07 | 2003-01-14 | Ariad Gene Therapeutics, Inc. | Intramuscular delivery of recombinant AAV |
US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
US6187757B1 (en) | 1995-06-07 | 2001-02-13 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using novel compounds |
WO1997031899A1 (en) | 1996-02-28 | 1997-09-04 | Ariad Gene Therapeutics, Inc. | Synthetic derivatives of rapamycin as multimerising agents for chimeric proteins with immunophilin derived domains |
US6723531B2 (en) | 1996-04-05 | 2004-04-20 | The Salk Institute For Biological Studies | Method for modulating expression of exogenous genes in mammalian systems, and products related thereto |
AU735648B2 (en) | 1996-07-12 | 2001-07-12 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
ATE545710T1 (de) | 1997-04-01 | 2012-03-15 | Illumina Cambridge Ltd | Verfahren zur vervielfältigung von nukleinsäuren |
US6548286B1 (en) | 1997-04-14 | 2003-04-15 | Cell Genesys, Inc. | Methods for increasing the efficiency of recombinant AAV product |
US6479653B1 (en) | 1997-08-26 | 2002-11-12 | Ariad Gene Therapeutics, Inc. | Compositions and method for regulation of transcription |
US6015709A (en) | 1997-08-26 | 2000-01-18 | Ariad Pharmaceuticals, Inc. | Transcriptional activators, and compositions and uses related thereto |
US6117680A (en) | 1997-08-26 | 2000-09-12 | Ariad Gene Therapeutics, Inc. | Compositions and methods for regulation of transcription |
AU752129B2 (en) | 1997-08-27 | 2002-09-05 | Ariad Gene Therapeutics, Inc. | Chimeric transcriptional activators and compositions and uses related thereto |
CA2318402A1 (en) | 1998-01-15 | 1999-07-22 | Ariad Gene Therapeutics, Inc. | Regulation of biological events using multimeric chimeric proteins |
US6984635B1 (en) | 1998-02-13 | 2006-01-10 | Board Of Trustees Of The Leland Stanford Jr. University | Dimerizing agents, their production and use |
WO1999041258A1 (en) | 1998-02-13 | 1999-08-19 | President And Fellows Of Harvard College | Novel dimerizing agents, their production and use |
US6333318B1 (en) | 1998-05-14 | 2001-12-25 | The Salk Institute For Biological Studies | Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto |
US6146874A (en) | 1998-05-27 | 2000-11-14 | University Of Florida | Method of preparing recombinant adeno-associated virus compositions |
US6258603B1 (en) | 1998-06-17 | 2001-07-10 | Rohm And Haas Company | Ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
US6200560B1 (en) | 1998-10-20 | 2001-03-13 | Avigen, Inc. | Adeno-associated virus vectors for expression of factor VIII by target cells |
US6221349B1 (en) | 1998-10-20 | 2001-04-24 | Avigen, Inc. | Adeno-associated vectors for expression of factor VIII by target cells |
US7109317B1 (en) | 1998-11-06 | 2006-09-19 | President And Fellows Of Harvard College | FK506-based regulation of biological events |
US6491907B1 (en) | 1998-11-10 | 2002-12-10 | The University Of North Carolina At Chapel Hill | Recombinant parvovirus vectors and method of making |
DK1916258T3 (da) | 1999-08-09 | 2014-07-28 | Genzyme Corp | Forøgelse af ekspression af en enkeltstrenget, heterolog nukleotidsekvens fra rekombinante, virale vektorer ved en sådan udformning af sekvensen at den danner intrastrengbasepar |
AU783158B2 (en) | 1999-08-24 | 2005-09-29 | Ariad Pharmaceuticals, Inc. | 28-epirapalogs |
US6780639B1 (en) | 1999-08-24 | 2004-08-24 | Universite Libre De Bruxelles | Antibiotic inducible/repressible genetic construct for gene therapy or gene immunization |
US7067526B1 (en) | 1999-08-24 | 2006-06-27 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
JP3961737B2 (ja) | 2000-02-29 | 2007-08-22 | 株式会社小糸製作所 | 車両用灯具およびその製造方法 |
US20040033600A1 (en) | 2001-03-21 | 2004-02-19 | Palli Subba Reddy | Ecdysone receptor-based inducible gene expression system |
AU2001249315A1 (en) | 2000-03-22 | 2001-10-03 | Rheogene, Inc. | Ecdysone receptor-based inducible gene expression system |
US7201898B2 (en) | 2000-06-01 | 2007-04-10 | The University Of North Carolina At Chapel Hill | Methods and compounds for controlled release of recombinant parvovirus vectors |
US8105825B2 (en) | 2000-10-03 | 2012-01-31 | Intrexon Corporation | Multiple inducible gene regulation system |
ES2385598T3 (es) | 2001-02-20 | 2012-07-27 | Intrexon Corporation | Sistema novedoso de expresión génica inducible basado en el receptor de ecdisona/receptor X retinoide de invertebrado |
JP4328094B2 (ja) | 2001-02-20 | 2009-09-09 | イントレクソン・コーポレイション | 新規置換突然変異体受容体および核受容体−ベースの誘導性遺伝子発現システムにおけるその使用 |
JP4955905B2 (ja) | 2001-02-20 | 2012-06-20 | イントレキソン コーポレーション | キメラレチノイドx受容体および新規エクジソン受容体−ベースの誘導性遺伝子発現システムにおけるそれらの使用 |
JP4994563B2 (ja) | 2001-02-20 | 2012-08-08 | イントレキソン コーポレーション | 新規置換突然変異体受容体および核受容体−ベースの誘導性遺伝子発現システムにおけるその使用 |
IL158487A0 (en) | 2001-05-18 | 2004-05-12 | Wisconsin Alumni Res Found | Method for the synthesis of dna sequences |
CA2406745C (en) | 2001-11-13 | 2006-01-10 | The Trustees Of The University Of Pennsylvania | A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby |
FI3517134T3 (fi) | 2001-12-17 | 2024-04-03 | Univ Pennsylvania | Adeno-assosioituneen viruksen (aav) serotyypin 8 sekvenssejä, niitä sisältäviä vektoreita ja niiden käyttöjä |
US20070015238A1 (en) | 2002-06-05 | 2007-01-18 | Snyder Richard O | Production of pseudotyped recombinant AAV virions |
US8005620B2 (en) | 2003-08-01 | 2011-08-23 | Dna Twopointo Inc. | Systems and methods for biopolymer engineering |
EP2434420A3 (en) | 2003-08-01 | 2012-07-25 | Dna Twopointo Inc. | Systems and methods for biopolymer engineering |
EP3211085B1 (en) | 2003-09-30 | 2021-03-31 | The Trustees of The University of Pennsylvania | Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor |
US20060246079A1 (en) | 2003-11-14 | 2006-11-02 | Morrow Phillip R | Neutralizing human antibodies to anthrax toxin |
US7935510B2 (en) | 2004-04-30 | 2011-05-03 | Intrexon Corporation | Mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
US7838657B2 (en) | 2004-12-03 | 2010-11-23 | University Of Massachusetts | Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences |
EP2357010B1 (en) | 2005-04-07 | 2013-06-12 | The Trustees of The University of Pennsylvania | Method of increasing the function of an AAV vector |
JP4495210B2 (ja) | 2005-06-09 | 2010-06-30 | パナソニック株式会社 | 振幅誤差補償装置及び直交度誤差補償装置 |
PL2548560T3 (pl) | 2005-06-23 | 2015-11-30 | Biogen Ma Inc | Kompozycje i sposoby modulowania splicingu SMN2 |
US8877187B2 (en) | 2005-07-25 | 2014-11-04 | Avianax, Llc | Therapeutic antibodies for treatment and prophylaxis of transmittable viral diseases |
EP2007795B1 (en) | 2006-03-30 | 2016-11-16 | The Board Of Trustees Of The Leland Stanford Junior University | Aav capsid proteins |
ES2400235T3 (es) * | 2006-04-28 | 2013-04-08 | The Trustees Of The University Of Pennsylvania | Método de producción escalable de AAV |
LT2489733T (lt) | 2006-06-07 | 2019-05-27 | Genzyme Corporation | Šoninės amiotrofinės sklerozės ir kitų nugaros smegenų sutrikimų genų terapija |
US8603950B2 (en) | 2007-02-20 | 2013-12-10 | Anaptysbio, Inc. | Methods of generating libraries and uses thereof |
JP5346820B2 (ja) | 2007-03-13 | 2013-11-20 | エイチユーエムエイビーエス・リミテッド・ライアビリティ・カンパニー | H5n1亜型a型インフルエンザウィルスに対する抗体 |
WO2008124934A1 (en) | 2007-04-17 | 2008-10-23 | National Research Council Of Canada | Constructs for enhancement of gene expression in muscle |
WO2008156763A2 (en) | 2007-06-15 | 2008-12-24 | The Board Of Trustees Of The Leland Stanford Junior University | Human neutralizing monoclonal antibodies to h5n1 influenza a virus |
US7863425B2 (en) | 2007-09-26 | 2011-01-04 | Cornell University | Compositions and methods for inhibiting Yersinia pestis infection |
NZ585500A (en) | 2007-11-12 | 2012-06-29 | Theraclone Sciences Inc | Antibodies which bind to an epitope in the extracellular domain of the matrix 2 ectodomain polypeptide of an influenza virus |
EP3333187B1 (en) | 2007-12-06 | 2022-06-22 | Dana-Farber Cancer Institute, Inc. | Antibodies against influenza virus and methods of use thereof |
ITTO20080204A1 (it) | 2008-03-17 | 2009-09-18 | Pomona Biotechnologies Llc | Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a |
JP2011516423A (ja) | 2008-03-28 | 2011-05-26 | シー レーン バイオテクノロジーズ, エルエルシー | ウイルス抗原に対する中和分子 |
ITTO20080398A1 (it) | 2008-05-27 | 2009-11-28 | Pomona Biotechnologies Llc | Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1 |
EP2296700A2 (en) | 2008-06-03 | 2011-03-23 | Vaxin, Inc. | Intranasal administration of receptor-binding ligands or genes encoding such ligands as a therapeutic regimen for mitigating infections caused by respiratory pathogens |
CA2731686C (en) | 2008-07-25 | 2020-04-07 | Institute For Research In Biomedicine | Neutralizing anti-influenza a virus antibodies and uses thereof |
US8871207B2 (en) | 2008-07-25 | 2014-10-28 | Humabs, LLC | Neutralizing anti-influenza A virus antibodies and uses thereof |
CN102245559B (zh) | 2008-11-07 | 2015-05-27 | 麻省理工学院 | 氨基醇类脂质和其用途 |
US8211631B2 (en) | 2008-12-18 | 2012-07-03 | Wisconsin Alumni Research Foundation | In vitro model of spinal muscular atrophy |
WO2010071832A1 (en) | 2008-12-19 | 2010-06-24 | Nationwide Children's Hospital | Delivery of polynucleotides across the blood brain barrier using recombinant aav9 |
AU2010247530B2 (en) | 2009-05-11 | 2016-10-13 | Janssen Vaccines & Prevention B.V. | Human binding molecules capable of neutralizing influenza virus H3N2 and uses thereof |
WO2010138263A2 (en) | 2009-05-28 | 2010-12-02 | University Of Massachusetts | Novel aav 's and uses thereof |
IT1395961B1 (it) | 2009-06-01 | 2012-11-02 | Pomona Biotechnologies Llc | Anticorpi monoclonali come medicamento per il trattamento terapeutico e/o profilattico delle infezioni da virus influenzale a (h1n1) di origine suina (s-oiv) |
EP3305302B1 (en) | 2009-06-17 | 2018-09-19 | Biogen MA Inc. | Compositions and methods for modulation of smn2 splicing in a subject |
CN102802666B (zh) | 2009-06-25 | 2015-06-03 | 米迪缪尼有限公司 | 猪流感血凝素变异体 |
US8598331B2 (en) | 2009-09-28 | 2013-12-03 | The University Of British Columbia | CLDN5 mini-promoters |
BR112012024934A2 (pt) | 2010-03-29 | 2016-12-06 | Univ Pennsylvania | sistemas de ablação de transgene induzida farmacologicamente |
US9315825B2 (en) | 2010-03-29 | 2016-04-19 | The Trustees Of The University Of Pennsylvania | Pharmacologically induced transgene ablation system |
US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
CN103492574B (zh) | 2011-02-22 | 2015-12-09 | 加州理工学院 | 使用腺相关病毒(aav)载体递送蛋白 |
EP3699286A1 (en) | 2011-04-20 | 2020-08-26 | The Trustees of the University of Pennsylvania | Regimens and compositions for aav-mediated passive immunization of airborne pathogens |
US20140127749A1 (en) | 2011-04-21 | 2014-05-08 | Arizona Borad Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizo | Methods of protein production and compositions thereof |
AU2012267531B2 (en) | 2011-06-08 | 2017-06-22 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mRNA delivery |
FR2977562B1 (fr) | 2011-07-06 | 2016-12-23 | Gaztransport Et Technigaz | Cuve etanche et thermiquement isolante integree dans une structure porteuse |
MX346206B (es) | 2011-07-14 | 2017-03-09 | Crucell Holland Bv | Moleculas de enlace humanas capaces de neutralizar los virus de la influenza a del grupo filogenetico 1 y grupo filogenetico 2 y virus de la influenza b. |
WO2013114885A1 (en) | 2012-01-31 | 2013-08-08 | Osaka University | Human monoclonal antibodies broadly protective against influenza b virus and methods of using the same |
US8834881B2 (en) | 2012-03-08 | 2014-09-16 | Crucell Holland B.V. | Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof |
WO2013155222A2 (en) | 2012-04-10 | 2013-10-17 | The Regents Of The University Of California | Brain-specific enhancers for cell-based therapy |
JP6208750B2 (ja) | 2012-06-08 | 2017-10-04 | エスリス ゲーエムベーハーethris GmbH | メッセンジャーrnaの肺送達 |
CA2877428A1 (en) | 2012-06-21 | 2013-12-27 | Association Institut De Myologie | Widespread gene delivery of gene therapy vectors |
DK2880053T3 (da) | 2012-08-01 | 2020-05-11 | Ikaika Therapeutics Llc | Lindring af vævsskade og fibrose via anti-LTBP4-antistof |
US9719106B2 (en) | 2013-04-29 | 2017-08-01 | The Trustees Of The University Of Pennsylvania | Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof |
KR102116378B1 (ko) | 2013-05-01 | 2020-06-01 | 젠자임 코포레이션 | 척수성 근위축증을 치료하기 위한 조성물 및 방법 |
EP3107582A4 (en) | 2014-02-19 | 2018-02-14 | Emergent BioSolutions Canada Inc. | Ebola monoclonal antibodies |
WO2015164757A1 (en) * | 2014-04-25 | 2015-10-29 | Oregon Health & Science University | Methods of viral neutralizing antibody epitope mapping |
EP3134115A4 (en) | 2014-04-25 | 2017-10-25 | The Trustees Of The University Of Pennsylvania | Methods and compositions for treating metastatic breast cancer and other cancers in the brain |
CA2946392A1 (en) | 2014-04-25 | 2015-10-29 | James M. Wilson | Ldlr variants and their use in compositions for reducing cholesterol levels |
JP6974943B2 (ja) | 2014-05-13 | 2021-12-01 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 2種の抗体構築物を発現するaavを含む組成物およびこの使用 |
CN113667696A (zh) * | 2014-09-24 | 2021-11-19 | 希望之城 | 用于高效基因组编辑的腺相关病毒载体变异体和其方法 |
US10894818B2 (en) | 2014-10-03 | 2021-01-19 | Massachusetts Institute Of Technology | Antibodies that bind Ebola glycoprotein and uses thereof |
BR112017016417A2 (pt) | 2015-02-05 | 2018-03-27 | Janssen Vaccines & Prevention B.V. | moléculas de ligação dirigidas contra hemaglutinina da gripe e seus usos |
EP3307310A2 (en) | 2015-05-13 | 2018-04-18 | The Trustees Of The University Of Pennsylvania | Aav-mediated expression of anti-influenza antibodies and methods of use thereof |
KR20180100304A (ko) | 2015-10-28 | 2018-09-10 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 유전자 요법을 위한 아데노-관련-바이러스 벡터의 척추강 내 투여 |
US11015173B2 (en) | 2015-12-11 | 2021-05-25 | The Trustees Of The University Of Pennsylvania | Scalable purification method for AAV1 |
US11098286B2 (en) | 2015-12-11 | 2021-08-24 | The Trustees Of The University Of Pennsylvania | Scalable purification method for AAV9 |
ES2918998T3 (es) | 2015-12-11 | 2022-07-21 | Univ Pennsylvania | Método de purificación escalable para AAVrh10 |
US11015174B2 (en) | 2015-12-11 | 2021-05-25 | The Trustees Of The University Of Pennsylvania | Scalable purification method for AAV8 |
US20180363000A1 (en) | 2015-12-14 | 2018-12-20 | The Trustees Of The University Of Pennsylvania | Aav-anti pcsk9 antibody constructs and uses thereof |
JP7082050B2 (ja) | 2015-12-14 | 2022-06-07 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 脊髄性筋萎縮症の処置において有用なアデノ-関連ウイルスベクター |
WO2017106244A1 (en) | 2015-12-14 | 2017-06-22 | The Trustees Of The University Of Pennsylvania | Compositions and methods for regulatable antibody expression |
WO2017136500A1 (en) | 2016-02-03 | 2017-08-10 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating mucopolysaccharidosis type i |
SG11201901221YA (en) * | 2016-08-15 | 2019-03-28 | Genzyme Corp | Methods for detecting aav |
WO2018057916A1 (en) | 2016-09-24 | 2018-03-29 | The Trustees Of The University Of Pennsylvania | Novel humanized anti-ebola antibodies useful in preventing ebola infections |
JOP20190200A1 (ar) | 2017-02-28 | 2019-08-27 | Univ Pennsylvania | تركيبات نافعة في معالجة ضمور العضل النخاعي |
CN110573523A (zh) | 2017-02-28 | 2019-12-13 | 宾夕法尼亚州大学信托人 | 基于aav载体的流感疫苗 |
JP7455579B2 (ja) | 2017-02-28 | 2024-03-26 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 新規アデノ随伴ウイルス(aav)クレードfベクター及びその用途 |
-
2018
- 2018-02-27 JP JP2019547088A patent/JP7455579B2/ja active Active
- 2018-02-27 SG SG10201912976WA patent/SG10201912976WA/en unknown
- 2018-02-27 SG SG10201912973XA patent/SG10201912973XA/en unknown
- 2018-02-27 CA CA3053399A patent/CA3053399A1/en active Pending
- 2018-02-27 WO PCT/US2018/019992 patent/WO2018160582A1/en active Application Filing
- 2018-02-27 PT PT187112024T patent/PT3589730T/pt unknown
- 2018-02-27 US US16/487,674 patent/US11827906B2/en active Active
- 2018-02-27 EP EP23183607.3A patent/EP4272765A3/en active Pending
- 2018-02-27 KR KR1020197027807A patent/KR20190132639A/ko not_active Application Discontinuation
- 2018-02-27 EP EP18711202.4A patent/EP3589730B1/en active Active
- 2018-02-27 PE PE2019001786A patent/PE20191362A1/es unknown
- 2018-02-27 FI FIEP18711202.4T patent/FI3589730T3/fi active
- 2018-02-27 LT LTEPPCT/US2018/019992T patent/LT3589730T/lt unknown
- 2018-02-27 MD MDE20200060T patent/MD3589730T2/ro unknown
- 2018-02-27 BR BR112019017839A patent/BR112019017839A2/pt unknown
- 2018-02-27 HR HRP20240257TT patent/HRP20240257T1/hr unknown
- 2018-02-27 CN CN201880028016.XA patent/CN110741082A/zh active Pending
- 2018-02-27 SG SG10201912969XA patent/SG10201912969XA/en unknown
- 2018-02-27 SI SI201831066T patent/SI3589730T1/sl unknown
- 2018-02-27 RS RS20240217A patent/RS65241B1/sr unknown
- 2018-02-27 SG SG11201907714UA patent/SG11201907714UA/en unknown
- 2018-02-27 DK DK18711202.4T patent/DK3589730T3/da active
- 2018-02-27 MX MX2019010275A patent/MX2019010275A/es unknown
-
2019
- 2019-08-12 IL IL26864419A patent/IL268644A/en unknown
- 2019-08-15 ZA ZA201905407A patent/ZA201905407B/en unknown
- 2019-08-27 CL CL2019002474A patent/CL2019002474A1/es unknown
- 2019-08-30 CO CONC2019/0009525A patent/CO2019009525A2/es unknown
-
2023
- 2023-04-12 JP JP2023064895A patent/JP2023089134A/ja active Pending
- 2023-10-11 US US18/484,856 patent/US20240117322A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20191362A1 (es) | Novedoso vector del subtipo f del virus adenoasociado (aav) y usos de este | |
CL2019002280A1 (es) | Vectores virales, adenovirales y composiciones a base de una secuencia de ornitina transcarbamilasa humana (hotch) modificada genéticamente y su uso en el tratamiento de deficiencia de la otc. (divisional solicitud 201602235) | |
CO2020004738A2 (es) | Variantes de cápsides de virus adenoasociados y métodos de uso de estas | |
UA124343C2 (uk) | Капсиди аденоасоційованого вірусу і спосіб його використання | |
CL2020002200A1 (es) | Nuevos vectores del virus adeno-asociado (aav), vectores que tienen desaminación de capside reducida y sus usos. | |
CL2020002201A1 (es) | Novedosos vectores de virus adenoasociado (aav), vectores de aav que tienen una desamidación reducida de la cápside y usos de estos. | |
CL2020001360A1 (es) | Cápsides variantes de virus adenoasociados y su uso para inhibir la angiogénesis. | |
CL2018000740A1 (es) | Vectores del factor viii del virus adeno-asociado, partículas víricas asociadas y formulaciones terapéuticas que los comprenden | |
BR112016018598A2 (pt) | vetor de vírus adeno-associados | |
UY37620A (es) | Vacunas contra la gripe mediadas por aav novedosas | |
RU2017142006A (ru) | Векторы на основе аденоассоциированных вирусов для лечения мукополисахаридозов | |
ES2629380T3 (es) | Viriones de AAV con inmunorreactividad reducida y usos de los mismos | |
EA202091712A1 (ru) | МОДИФИЦИРОВАННЫЙ КАПСИДНЫЙ БЕЛОК rAAV ДЛЯ ГЕННОЙ ТЕРАПИИ | |
AR110502A1 (es) | Polinucleótidos y polipéptidos de adenovirus | |
EA201791936A1 (ru) | Рекомбинантные конструкции glut1 аденоассоциированного вирусного вектора и способы восстановления экспрессии glut1 на их основе | |
CO2020002283A2 (es) | Métodos de terapia génica del factor viii (fviii) | |
MX2021012311A (es) | Variantes de capsides de aav para liberacion intravitrea. | |
PH12020500569A1 (en) | Influenza virus vaccines and uses thereof | |
CO2022001833A2 (es) | Proteína vp1 modificada aislada de la cápside del virus adeno-asociado de serotipo 5 (aav5), cápside y vector basado en la misma. | |
CL2021002236A1 (es) | Inserción de vectores de virus adeno-asociados de b-sarcoglicano y el tratamiento de distrofia muscular | |
CO2022016956A2 (es) | Composiciones útiles en el tratamiento del trastorno de deficiencia de cdkl5 (cdd) | |
CO2018001339A2 (es) | Sistema vector de adenovirus aviar 9 (fadv-9) y métodos asociados | |
MX2022000551A (es) | Proteínas de la cápside de aav modificadas para el tratamiento de una enfermedad artrítica. | |
EA201992023A1 (ru) | Вектор на основе аденоассоциированного вируса (aav) клады f и его применения | |
EA202091194A1 (ru) | Вирусные векторы, содержащие области, кодирующие rdh12, и способы лечения дистрофий сетчатки |